The difference in OS of patients with MYCN-amplified neuroblastoma showed a significant difference (p=0.027), which shows that MYCN-amplified tumors show a better response to DFMO over MYCN non-amplified tumors [54]. Table 4 shows a comparison of EFS and OS between NMTR0032/003b and the control group (BCC001). Here, MYCN is linked to neuroblastoma.